These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 15727333)
1. [Endocannabinoid and endocannabinoid receptor antagonists]. Heinzl S Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333 [No Abstract] [Full Text] [Related]
2. Drug development. Drugs inspired by a drug. Marx J Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309 [No Abstract] [Full Text] [Related]
3. Impairments in endocannabinoid signaling and depressive illness. Hill MN; Gorzalka BB JAMA; 2009 Mar; 301(11):1165-6. PubMed ID: 19293417 [No Abstract] [Full Text] [Related]
4. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Ducobu J; Sternon J J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510 [TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873 [TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid control of food intake and energy balance. Di Marzo V; Matias I Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067 [TBL] [Abstract][Full Text] [Related]
7. Minireview: Endocannabinoids and their receptors as targets for obesity therapy. de Kloet AD; Woods SC Endocrinology; 2009 Jun; 150(6):2531-6. PubMed ID: 19372200 [TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions. Sander GE; Giles TD Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895 [No Abstract] [Full Text] [Related]
10. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932 [TBL] [Abstract][Full Text] [Related]
11. Molecule of the month. Rimonabant hydrochloride. Drug News Perspect; 2004; 17(6):403. PubMed ID: 15334190 [No Abstract] [Full Text] [Related]
12. Soothing the seizures of children. Lutz B; Monory K Nat Med; 2008 Jul; 14(7):721-2. PubMed ID: 18607372 [No Abstract] [Full Text] [Related]
13. [Pharmacology of cannabinoid receptors]. Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447 [TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system as a target for obesity treatment. Aronne LJ; Pagotto U; Foster GD; Davis SN Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740 [TBL] [Abstract][Full Text] [Related]
16. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063 [No Abstract] [Full Text] [Related]
17. Endocannabinoids and their role in fatty liver disease. Mallat A; Lotersztajn S Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921 [TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system: a new pharmacological target for obesity treatment? Hu J; Zhu C; Huang M Neurosci Bull; 2009 Jun; 25(3):153-60. PubMed ID: 19448689 [TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system and the control of glucose homeostasis. Nogueiras R; Rohner-Jeanrenaud F; Woods SC; Tschöp MH J Neuroendocrinol; 2008 May; 20 Suppl 1():147-51. PubMed ID: 18426514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]